Related Experiment Video

Updated: Oct 12, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention

    Prescrire International
    |September 30, 2000
    PubMed

    Insights

    Aspirin effectively reduces mortality and complications from myocardial infarction and angina. Optimal daily doses range from 75-350 mg, with specific combinations recommended for acute care and interventional procedures.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Preventive Medicine

    Background:

    • Aspirin is a widely used antiplatelet agent with established benefits in cardiovascular disease.
    • Understanding optimal dosing and combinations is crucial for maximizing efficacy and minimizing risks.

    Purpose of the Study:

    • To review the evidence on aspirin's efficacy in various cardiovascular conditions.
    • To define optimal aspirin dosages and therapeutic combinations.
    • To explore alternative antiplatelet strategies when aspirin is not suitable.

    Main Methods:

    • Systematic review of clinical trials and observational studies.
    • Analysis of data on aspirin's impact on mortality, myocardial infarction, and procedural complications.
    • Evaluation of different aspirin dosages and combination therapies.

    Main Results:

    • Aspirin significantly reduces acute-phase mortality post-myocardial infarction and lowers risks in unstable and stable angina.
    • Recommended daily aspirin dosage for optimal risk-benefit is 75-350 mg, with 160 mg validated for acute myocardial infarction.
    • Combinations with thrombolytics, heparin, clopidogrel, or ticlopidine are discussed, with clopidogrel potentially superior to ticlopidine during stenting.

    Conclusions:

    • Aspirin is a cornerstone therapy for preventing cardiovascular events and complications.
    • Tailoring aspirin dosage and combination therapy based on clinical context is essential.
    • Clopidogrel serves as an alternative when aspirin is contraindicated, and oral anticoagulants may be preferred after complicated myocardial infarction.

    Related Concept Videos

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...